跳至主要内容
临床试验/JPRN-UMIN000034438
JPRN-UMIN000034438招募中未知

Phase II trial on the effectiveness and safety of bariatric surgery for advanced obesity - Phase II trial on the effectiveness and safety of bariatric surgery

Wakayama Medical University0 个研究点目标入组 24 人开始时间: 2018年10月10日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
入组人数
24

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
20years-old 至 65years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1. History of bariatric surgery 2. Currently pregnant or nursing 3. Receiving steroids or immune suppressor 4. Uncontrollable infection 5. Patients who need treatment of Ischemic heart disease 6. Liver cirrhosis of active hepatitis 7. Patients with respiratory disease and require oxygen therapy 8. Patients with renal dysfunction and require dialysis 9. Active cancer of any kind 10. Patients who have history of upper abdominal surgery and cannot accept laparoscopic surgery 11. Cases in which surgeon cannot perform safety operation 12. Patients uncooperative to treatment

研究者

相似试验

已完成
2 期
An early phase II trial for efficacy and safety of TTA-121 on autism spectrum disorderAutism spectrum disorder
JPRN-UMIN000031412Hamamatsu University School of Medicine, Department of Psychiatry144
进行中(未招募)
1 期
Multinational, multicenter, phase 2 study of the efficacy and safety of ABY-035 in treating and preventing relapse/recurrence of disease activity in subjects with non-infectious intermediate, posterior or pan-uveitis.non-infectious intermediate, posterior, or pan-uveitisMedDRA version: 20.0Level: PTClassification code 10046851Term: UveitisSystem Organ Class: 10015919 - Eye disorders
EUCTR2020-004964-25-ITAffibody AB110
进行中(未招募)
1 期
Multinational, multicenter, phase 2 study of the efficacy and safety of ABY-035 in treating and preventing relapse/recurrence of disease activity in subjects with non-infectious intermediate, posterior or pan-uveitis.non-infectious intermediate, posterior, or pan-uveitisMedDRA version: 20.0Level: PTClassification code 10046851Term: UveitisSystem Organ Class: 10015919 - Eye disorders
EUCTR2020-004964-25-ESAffibody AB110
进行中(未招募)
1 期
Multinational, multicenter, phase 2 study of the efficacy and safety of ABY-035 in treating and preventing relapse/recurrence of disease activity in subjects with non-infectious intermediate, posterior or pan-uveitis.non-infectious intermediate, posterior, or pan-uveitisMedDRA version: 20.0Level: PTClassification code 10046851Term: UveitisSystem Organ Class: 10015919 - Eye disorders
EUCTR2020-004964-25-DEAffibody AB20
进行中(未招募)
1 期
A phase II study assessing safety and efficacy of Cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failureRecurrent unresectable or metastatic cervix carcinomaMedDRA version: 21.1Level: PTClassification code 10008344Term: Cervix carcinoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2019-002184-97-FRCentre François Baclesse57
Phase II trial on the effectiveness and safety of... | 临床试验